Genmab A/S (NASDAQ:GMAB – Get Free Report) has received a consensus rating of “Hold” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $45.20.
A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. BTIG Research increased their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Morgan Stanley reissued an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 4th. Truist Financial reduced their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, August 27th.
Get Our Latest Stock Analysis on GMAB
Hedge Funds Weigh In On Genmab A/S
Genmab A/S Stock Up 0.1 %
GMAB opened at $27.50 on Wednesday. Genmab A/S has a 52 week low of $24.53 and a 52 week high of $38.80. The business has a fifty day simple moving average of $27.16 and a 200-day simple moving average of $28.10. The firm has a market cap of $18.19 billion, a P/E ratio of 22.92, a P/E/G ratio of 0.87 and a beta of 0.99.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. Sell-side analysts expect that Genmab A/S will post 1.21 earnings per share for the current year.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- What is an Earnings Surprise?
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- What is a Death Cross in Stocks?
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.